Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
In the year-ago quarter, Kymera reported a loss of 25 cents per share. The year-over-year deterioration was due to lower collaboration revenues and higher operating expenses. Collaboration revenues totaled $7.4 million, which missed the Zacks Consensus Estimate of $13 million. In the year-ago quarter, Kymera earned collaboration revenues of $47.9 million due to the recognition of milestone payments related to the advancement of KT-474 into phase II testing under its collaboration with pharma bigwig Sanofi SNY. Shares of KYMR have lost 30.1% year to date compared with the industry's decline of 8%. Zacks Investment Research Image Source: Zacks Investment Research Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. KYMR's Operating Expenses Increase in Q4 Research and development expenses totaled $71.8 million, up 35.6% year over year. This was primarily due to increased expenses related to the investment in the STAT6 and TYK2 degrader programs, pl
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Kymera gains Fast Track status for oral candidate KT-621 for eczema [Seeking Alpha]Seeking Alpha
- Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Stephens.MarketBeat
KYMR
Earnings
- 11/4/25 - Miss
KYMR
Sec Filings
- 12/17/25 - Form 4
- 12/17/25 - Form 4
- 12/17/25 - Form 144
- KYMR's page on the SEC website